Sensitization to Cor a 9 and Cor a 14 is highly specific for a severe hazelnut allergy in Dutch children and adults

  • L Masthoff
  • L Mattsson
  • L Zuidmeer-Jongejan
  • J Lidholm
  • K Andersson
  • JH Akkerdaas
  • SA Versteeg
  • C Garino
  • Y Meijer
  • P Kentie
  • A Versluis
  • CF den Hartog Jager
  • CA Bruijnzeel-Koomen
  • AC Knulst
  • R van Ree
  • E van Hoffen
  • SG Pasmans
Open Access
Oral presentation
  • 671 Downloads

Keywords

Public Health Allergic Reaction Food Allergy Single Component Subjective Symptom 

Background

Component-resolved diagnosis has been shown to improve diagnosis of food allergy. The aim of this study was to evaluate whether component-resolved diagnosis may help to identify patients at risk of severe allergic reactions to hazelnut.

Methods

A total of 161 hazelnut-sensitized patients were included: 40 children and 15 adults with objective symptoms in DBPCFC and 24 adults with a convincing severe history were compared to 41 children and 41 adults with no or subjective symptoms in DBPCFC (grouped together). IgE levels to hazelnut extract and single components were analyzed with ImmunoCAP.

Results

IgE to hazelnut extract was significantly higher in children with severe than with no or mild symptoms. Sensitization to rCor a 1.04 was common among both children and adults, while sensitization to rCor a 8 was rare. In 13% of children and 49% of adults with a severe hazelnut allergy, only sensitization to rCor a 1.04 was observed and not to other water-soluble allergens. Sensitization to nCor a 9 and/or rCor a 14 was strongly associated with a severe hazelnut allergy. Using adapted cut-off levels, a diagnostic discrimination between severity groups was obtained. IgE to either nCor a 9 ≥1 kUA/L or rCor a 14 ≥5 kUA/L (children) and IgE to either nCor a 9 ≥1 kUA/L or rCor a 14 ≥1 kUA/L (adults) had a specificity of >90% and accounted for 83% of children and 44% of adults with a severe hazelnut allergy.

Conclusion

Sensitization to Cor a 9 and Cor a 14 is highly specific for patients with objective symptoms in DBPCFC as marker for a more severe hazelnut allergic phenotype.

Disclosure of interest

None declared.

Copyright information

© Masthoff et al; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Authors and Affiliations

  • L Masthoff
    • 1
  • L Mattsson
    • 2
  • L Zuidmeer-Jongejan
    • 3
  • J Lidholm
    • 2
  • K Andersson
    • 2
  • JH Akkerdaas
    • 3
  • SA Versteeg
    • 3
  • C Garino
    • 4
  • Y Meijer
    • 5
  • P Kentie
    • 5
  • A Versluis
    • 1
  • CF den Hartog Jager
    • 1
  • CA Bruijnzeel-Koomen
    • 1
  • AC Knulst
    • 1
  • R van Ree
    • 3
  • E van Hoffen
    • 1
  • SG Pasmans
    • 1
  1. 1.Dermatology/AllergologyUniversity Medical Center UtrechtUtrechtthe Netherlands
  2. 2.Thermo Fisher ScientificUppsalaSweden
  3. 3.Experimental ImmunologyAcademic Medical CenterAmsterdamthe Netherlands
  4. 4.Pharmaceutical Sciences, Drug & Food Biotechnology CenterUniversity of Piemonte Orientale "A. Avogadro"NovaraItaly
  5. 5.Pediatric Pulmonology/AllergologyUniversity Medical Center UtrechtUtrechtthe Netherlands

Personalised recommendations